Compare Deere & Company (DE) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Enveric Biosciences Inc — how do they compare? Deere & Company trades at $578.61 (market cap $157.75B), while Enveric Biosciences Inc trades at $1.33 (market cap $5.32M). The key difference: Deere & Company is far larger — about 29652.3× Enveric Biosciences Inc's market cap, and Deere & Company pays a 1.11% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| DE | ENVB | |
|---|---|---|
Market Cap | $157.75B | $5.32M |
Sector | Industrials | Health |
52-Week High | $662.49 | $17.40 |
52-Week Low | $439.11 | $1.28 |
Enterprise Value | $212.58B | $408.82K |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $585.64, down 0.21% on the day, with a bearish technical signal from moving averages and oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue declined to $44.67B in 2025, though net income margin remains solid at 10.33%. Recent news highlights a $20B precision agriculture initiative and regulatory agreements enhancing farmer access to repair tools.
The outlook is mixed: analyst consensus targets $676.08 (15% upside) with 41% buy ratings, but technicals and declining revenue pose near-term risks. Key opportunities include margin strength and agtech growth; risks involve cyclical farming demand and high debt levels. Investors should weigh fundamental resilience against sector headwinds.
ENVB trades at $1.33, down 1.48% on the day, with a bearish technical signal from moving averages despite neutral oscillators. The company shows significant financial challenges with negative ROE of -257.95% and ROA of -218.01%, though it has consistently beaten earnings expectations in recent quarters. Recent news highlights active participation in investor conferences and progress with EB-003 drug candidate development.
While analyst consensus is 75% buy-rated, the stock faces substantial fundamental risks from negative profitability and cash burn. Investment opportunity exists if clinical developments succeed, but shareholders should weigh high operational losses against potential biotech breakthroughs in the neuroplastogenic therapeutics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
